Pulmonx Corp (LUNG-Q) Stock Price and News
This article provides current stock information for Pulmonx Corp (LUNG-Q), including its NASDAQ ticker, real-time price updates, and recent trading data. It also includes a news feed with analyst ratings, earnings call transcripts, and corporate announcements related to the company. Pulmonx Corporation is described as a medical technology company specializing in minimally invasive devices for chronic obstructive pulmonary diseases, based in Redwood City, California.
Pulmonx Corp Officer Radhakrishnan Srikanth Sells 14,245 Shares at $2.26 Each (NASDAQ: LUNG)
Radhakrishnan Srikanth, Chief Science & Technology Officer of Pulmonx Corp (NASDAQ: LUNG), sold 14,245 shares of the company stock in four separate transactions on September 1, 2026, at a price of $2.26 per share. Following these sales, Srikanth retains ownership of 316,994 shares of Pulmonx Corp. All transactions were filed with the SEC under transaction code S.
Pulmonx (LUNG) general counsel sells shares to cover RSU taxes
Pulmonx Corp's General Counsel, David Aaron Lehman, sold 14,334 shares of common stock on September 1, 2026, for $2.26 per share across four transactions. These sales were made to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted between 2023 and 2026. After these transactions, Lehman directly holds 361,827 shares of common stock.
Pulmonx general counsel David Lehman sells $32,393 in stock By Investing.com
David Lehman, General Counsel of Pulmonx Corp (NASDAQ:LUNG), sold 14,334 shares of company stock totaling $32,393 on September 1, 2026. These sales were executed to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) granted between 2023 and 2026. Following these transactions, Lehman directly holds 361,827 shares, while the company's stock trades at $2.26, showing a 48% increase over six months.
Pulmonx (LUNG) exec sells shares to cover RSU taxes
Pulmonx's Chief Commercial Officer, Rose Geoffrey Beran, sold 7,879 shares of common stock at $2.26 per share on September 1, 2026. These sales were not discretionary but were made to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted between 2023 and 2026. The filing indicates a neutral impact but negative sentiment, confirming the transactions were for tax purposes and not under a Rule 10b5-1 trading plan.
Pulmonx (LUNG) CEO sells 41,882 shares to cover taxes
Pulmonx Corp's President and CEO, Glendon E. French III, sold 41,882 shares of common stock at $2.26 per share on September 1, 2026. These sales were conducted to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted in 2023 and 2025. Following these transactions, French indirectly holds 918,198 shares through a family trust, and the sales were not made under a Rule 10b5-1 trading plan.
Pulmonx CEO French Glendon E. III Disposes of 41,882 Shares at $2.26 Each
Pulmonx Corp's President and CEO, French Glendon E. III, sold 41,882 shares at $2.26 each in two separate transactions on September 1, 2026. Following these sales, his ownership stake in Pulmonx Corp (NASDAQ: LUNG) is 1,137,936 shares. These transactions were reported under SEC transaction code S.
Pulmonx general counsel David Lehman sells $32,393 in stock
David Aaron Lehman, General Counsel of Pulmonx Corp (NASDAQ:LUNG), sold 14,334 shares of company stock for a total of $32,393 on September 1, 2026. These sales were primarily to cover tax withholding obligations related to vested Restricted Stock Units (RSUs) granted over several years. Following the transactions, Lehman directly holds 361,827 shares, as Pulmonx shares have seen a 48% increase over the past six months, despite a recent 7% decline, and the company reported better-than-expected Q2 2026 financial results.
Pulmonx CCO Geoffrey Rose sells $17,804 in lung shares
Pulmonx's Chief Commercial Officer, Geoffrey Rose, sold 7,879 shares of the company's common stock for $17,804 to cover tax obligations from vested Restricted Stock Units. Following these sales, he still directly holds 449,832 shares. This insider transaction comes as LUNG stock has seen significant growth and the company recently surpassed Q2 2026 financial expectations.
Pulmonx chief science officer sells $32,192 in stock
Pulmonx's Chief Science & Technology Officer, Srikanth Radhakrishnan, sold 14,245 shares of company stock for $32,192 to cover tax withholding obligations from RSU vestings. Despite the sale, Radhakrishnan still directly owns 316,994 shares. The company recently surpassed analyst expectations for its Q2 2026 earnings, contributing to a strong 48% return for LUNG shares over the past six months, although InvestingPro suggests the stock is still undervalued.
Insider at Pulmonx (LUNG) sells shares to cover taxes
Pulmonx's Chief Science & Technology Officer, Radhakrishnan Srikanth, sold 14,245 shares of common stock at $2.26 per share on September 1, 2026. These sales were executed across four transactions to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted between March 2023 and March 2026. The filing indicates no Rule 10b5-1 trading plan was in place for these transactions.
Pulmonx to Participate in Upcoming Investor Conferences
Pulmonx Corporation announced its participation in two upcoming investor conferences: the Wells Fargo Healthcare Conference on September 9 in Boston, and the Lake Street Best Ideas Growth (BIG10) Conference on September 10 in New York, both featuring 1x1 meetings. The company, a leader in minimally invasive treatments for severe lung disease, will have its management present at these events. Pulmonx is known for its Zephyr® Endobronchial Valve and other related systems for treating COPD.
Pulmonx Corp. Revenue Breakdown – LS:A2P1AF
Pulmonx Corp. (A2P1AF) generated 77.05 million EUR in revenue last year, primarily from its Interventional Pulmonology segment. This marks a slight decrease from the previous year's revenue of 80.94 million EUR. The United States was the largest contributor to revenue, accounting for 48.55 million EUR.
What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?
Pulmonx Corporation (LUNG) has been identified as a strong momentum stock by Zacks Equity Research, boasting a Momentum Style Score of B and a Zacks Rank of #2 (Buy). The company has shown significant short-term and long-term price performance, outperforming both its industry and the S&P 500. Positive earnings estimate revisions further contribute to its promising outlook for investors seeking near-term growth.
Morgan Stanley (LUNG) reports 6.9% Pulmonx stake in updated ownership filing
Morgan Stanley and Morgan Stanley Capital Services LLC have filed an amended Schedule 13G, disclosing their beneficial ownership in Pulmonx Corp (LUNG). Morgan Stanley reports a 6.9% stake, representing 2,920,241 shares, while Morgan Stanley Capital Services LLC reports a 6.8% stake, or 2,885,147 shares. All reported shares are held with shared voting and dispositive power.
Pulmonx (LUNG) Q2 2026 Earnings Call Transcript
Pulmonx (LUNG) reported its Q2 2026 earnings, highlighting a 34% reduction in net loss and a 39% decrease in adjusted EBITDA loss, driven by cost alignment initiatives. The company reiterated its full-year revenue guidance of $90 million to $92 million and expects to return to year-over-year sales growth later in 2026, partly due to the renewal of its Chinese registration certificate and stabilizing U.S. sales force. Pulmonx also emphasized the potential of its AeriSeal product to expand the total addressable market by approximately 20% globally, with CONVERT II trial enrollment on track for completion in 2027.
Pulmonx Corp 2026: Revenue $22.76M, EPS ($0.24) — 10-Q Summary
Pulmonx Corp reported its 2026 quarterly results, showing revenue of $22.76 million and a diluted EPS of ($0.24), an improvement from the prior year. The company experienced a decline in revenue due to lower procedure volumes, particularly in the U.S. and China, but saw an improved gross margin and continued commercial expansion efforts.
Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?
Pulmonx (LUNG) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates. The Zacks rating system highlights the strong correlation between changes in future earnings potential and near-term stock price movements, suggesting positive investor sentiment and potential for stock appreciation. This upgrade places Pulmonx in the top 20% of Zacks-covered stocks based on estimate revisions, indicating a strong candidate for market-beating returns.
Earnings Release: Here's Why Analysts Cut Their Pulmonx Corporation (NASDAQ:LUNG) Price Target To US$3.40
Pulmonx Corporation's Q2 results showed revenues in line with predictions and smaller-than-expected statutory losses. Despite the positive earnings surprise, analysts have lowered their average price target to US$3.40, indicating reduced optimism about the company's future valuation. While revenue growth is expected to slow, it is still projected to align with the industry average.
Lake Street Maintains Pulmonx(LUNG.US) With Buy Rating, Maintains Target Price $4
Lake Street has reiterated its Buy rating for Pulmonx (LUNG.US) and maintained its price target at $4. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Pulmonx Affirms FY26 Sales Guidance of $90.000M-$92.000M
Pulmonx (NASDAQ: LUNG) has reiterated its full-year 2026 sales guidance, keeping the range at $90.000 million to $92.000 million. This guidance is consistent with previous statements and aligns closely with the consensus analyst estimate of $90.832 million. The affirmation signals management's confidence in the company's operational performance and ability to meet financial targets for the fiscal year.
Pulmonx Corp Q2 revenue falls, but beats estimates
Pulmonx Corp's Q2 revenue experienced a decline but still managed to surpass analyst estimates. The article, sourced from Reuters via TradingView News, provides a brief update on the company's financial performance.
Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates
Pulmonx Corporation (LUNG) reported a Q2 loss of $0.24 per share, surpassing the Zacks Consensus Estimate of a $0.28 loss, and also beat revenue expectations with $22.76 million. Despite underperforming the market year-to-date, the company has consistently topped revenue estimates in the past four quarters, and its stock currently holds a Zacks Rank #3 (Hold).
LUNG|Pulmonx Corp|Price:1.245|Chg%:-0.005
This article provides a detailed financial overview of Pulmonx Corp (LUNG), including its stock performance, key financial indicators, and historical data. It presents an all-in-one data dashboard for smart investors, organizing complex financial statements into customizable views. The report covers the income statement, balance sheet, and cash flow statement, highlighting the latest annual financial report and quarterly performance breakdowns.
Pulmonx Q2 Revenue Falls 5 Percent To $22.8 Million
Pulmonx (LUNG) reported a 5% decline in Q2 2026 revenue to $22.8 million, down from $23.9 million a year earlier, though its net loss narrowed to $10.1 million. The company maintained its full-year 2026 revenue outlook of $90 million to $92 million. Insider trading data shows significant sales by company executives, while institutional investors show mixed activity with some increasing and others decreasing their positions.
BlackRock (LUNG) updates Pulmonx Corp stake, reports 765,721 shares owned
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 765,721 shares of Pulmonx Corp (LUNG) common stock, which represents 1.8% of the class. BlackRock holds sole voting and sole dispositive power over all these shares, with no shared power. The filing notes that beneficiaries with rights to dividends or sale proceeds are various clients, none of whom hold more than five percent of Pulmonx's outstanding common shares.
Pulmonx Corp. Revenue Breakdown – LSX:A2P1AF
Pulmonx Corp. (LSX:A2P1AF) generated €77.05 million in revenue last year, primarily from its Interventional Pulmonology segment. The United States was the largest contributor to revenue, accounting for €48.55 million in the past year. This report provides a breakdown of the company's financial performance by segment and region.
Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference
Pulmonx Corporation, a leader in minimally invasive treatments for severe lung disease, announced its participation in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference. The event is scheduled for Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET. A live and archived webcast will be available on the Investors section of the Pulmonx website.
Pulmonx's Aug. 11 Boston fireside chat will be webcast live
Pulmonx (Nasdaq: LUNG) announced it will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET. A live and archived webcast of the event will be accessible through the Investors section of the company's website. Pulmonx is a global leader in minimally invasive treatments for severe lung disease.
Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference
Pulmonx Corporation will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. The event, taking place in Boston, will also be accessible via a live and archived webcast on the "Investors" section of the company's website. Pulmonx is a global leader in minimally invasive treatments for severe lung disease, known for its Zephyr Endobronchial Valve and other related technologies.
LUNG|Pulmonx Corp|Price:1.225|Chg%:+0.055
This article from TradingKey provides a comprehensive stock analysis of Pulmonx Corp (LUNG), highlighting its relatively healthy fundamentals, significant growth potential, and "fairly valued" status within the Healthcare Equipment & Supplies industry. It notes high institutional ownership and recent "Buy" ratings from analysts with a target price indicating substantial upside. The analysis also details the company's products for COPD treatment and outlines its strengths, risks, and various scoring methodologies used by TradingKey.
Pulmonx Corp (LUNG) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Pulmonx Corp (LUNG), listing its major shareholders and their proportions, as well as categorizing shareholder types. It also provides institutional shareholding data over several quarters and recent shareholder activity. Additionally, the article lists related ETFs that include Pulmonx Corp.
Pulmonx Corp expected to post a loss of 28 cents a share - Earnings Preview
Pulmonx Corp (NASDAQ: LUNG) is anticipated to report a loss of 28 cents per share in its upcoming earnings announcement. This information, provided by Refinitiv, suggests the company is facing an expected negative financial outcome for the period.
Pulmonx Market Sentiment
This article analyzes the market sentiment for Pulmonx (LUNG) based on analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from 9 analysts with an average price target of $8, a 3.2% short float, and no recent insider activity. The article also provides a detailed table of recent analyst actions, including ratings, price target changes, and actions by various firms.
Pulmonx Corp. Revenue Breakdown – MUN:4NI
This article provides a revenue breakdown for Pulmonx Corp. (MUN:4NI), showing that its top-performing segment, Interventional Pulmonology, generated €77.05 million last year, down from €80.94 million in the prior year. The United States was the greatest contributor, accounting for €48.55 million, a decrease from the previous year's €54.54 million.
Pulmonx Corp (LUNG) Cash Flow
This article provides a detailed cash flow statement for Pulmonx Corp (LUNG), including operating, investing, and financing cash flows presented quarterly and annually. It outlines key financial metrics and offers definitions for different types of cash flow, along with Pulmonx Corp's specific figures for recent periods. The data helps evaluate the company's financial health, investment activities, and funding strategies.
Pulmonx Corp (LUNG) Financial Health: Profitability & Balance Sheet Analysis
The article provides a financial health analysis of Pulmonx Corp (LUNG), noting its current financial score of 6.77, ranking 133rd in the Healthcare Equipment & Supplies industry. It highlights a stable financial status but low operating efficiency, with recent quarterly revenue decreasing by 8.66% year-over-year and net profit decreasing by 5.50% year-over-year. The analysis covers aspects like financial health, quality of earnings, operational efficiency, growth potential, and shareholder returns, though some detailed data points are noted as not disclosed by the company.
LUNG|Pulmonx Corp|Price:1.225|Chg%:+0.055
This article provides a detailed overview of Pulmonx Corp (LUNG), a commercial-stage medical technology company specializing in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). It highlights the company's key products, including the Zephyr Endobronchial Valve and Chartis Pulmonary Assessment System, and lists its executive team and top shareholders. The financial data shows a market cap of $51.74 million and recent stock performance.
Pulmonx Corp (LUNG) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Pulmonx Corp (LUNG) focusing on its dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent payouts. The article includes current stock pricing and market capitalization information for Pulmonx Corp.
Pulmonx Corp (LUNG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Pulmonx Corp (LUNG), focusing on its regional revenue contributions. As of the specified date, the company has not yet disclosed detailed data for business segments or specific quarterly financial years. The primary revenue source is the United States, followed by Europe, Middle-East and Africa ("EMEA"), and Asia Pacific.
TradingKey
This article provides a detailed quarterly and annual income statement for Pulmonx Corp (LUNG), offering financial insights into its revenue, operating expenses, and net income. It also includes frequently asked questions about interpreting income statements and key metrics for analyzing LUNG stock. The data covers several fiscal years and quarters, highlighting year-over-year changes in various financial figures.
Pulmonx Corp (LUNG) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Pulmonx Corp (LUNG), noting its current valuation score of 7.71, which ranks 138 out of 200 in the Healthcare Equipment & Supplies industry. The company's P/E ratio is reported as -0.91, and other key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed. The data was last updated on July 24, 2026.
LUNG|Pulmonx Corp|Price:1.220|Chg%:+0.010
Pulmonx Corp (LUNG) closed at 1.170 USD, down 4.10%. The company, a commercial-stage medical technology firm specializing in COPD treatments, shows strong fundamentals and significant growth potential despite a recent weak stock market performance. Analysts rate it a "Buy" with a target price of 3.40, indicating a 178.69% upside.
Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
Pulmonx Corporation announced it will release its second-quarter 2026 financial results on Wednesday, July 29, 2026, after the close of trading. The company will host a conference call to discuss these results at 1:30 p.m. PT / 4:30 p.m. ET, with a webcast available on its investor relations website. Pulmonx is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD).
Pulmonx Sets July 29 Webcast to Discuss Second-Quarter Results
Pulmonx (Nasdaq: LUNG) announced it will release its second-quarter 2026 financial results after market close on Wednesday, July 29, 2026. The company will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, which will be accessible via their investor relations website. This announcement notes a mixed historical market reaction to similar notices, with an average stock move of 1.66%.
Pulmonx (NASDAQ:LUNG) Sparks Fresh Penny Stock Buzz
Pulmonx (NASDAQ:LUNG) is attracting attention as a penny stock due to its focus on severe emphysema treatment. The company's key products, the Zephyr Endobronchial Valve and the Chartis system, are highlighted for their role in improving lung function in affected patients. This renewed interest is driven by the strength of the healthcare sector and Pulmonx's innovative medical devices.
Enterprise value to EBIT forward of Pulmonx Corporation – NASDAQ:LUNG
This article briefly highlights the enterprise value to EBIT forward for Pulmonx Corporation (NASDAQ:LUNG). It indicates that the market is currently closed with no trades recorded. The data is provided by ICE Data Services and FactSet, with SEC filings from Quartr.
Pulmonx Corp highlights lung device strategy as a specialized medtech player
Pulmonx Corp positions itself as a specialized medical technology company focusing on minimally invasive devices for severe emphysema and chronic respiratory conditions. Its business model centers on bronchoscopic procedures, generating revenue from implantable devices and associated delivery systems used by specialist physicians. The company's strategy emphasizes regulatory clearances, reimbursement, and clinical evidence to drive adoption and long-term growth in the respiratory care market.
Enterprise value to EBITDA forward of Pulmonx Corp. – LSX:A2P1AF
This page from TradingView provides financial information for Pulmonx Corp. under the ticker LSX:A2P1AF. It focuses on the enterprise value to EBITDA forward metric, but the actual data values are not visible in the provided content. The page also includes various navigation and informational links related to trading and financial analysis tools.
Enterprise value to EBIT forward of Pulmonx Corp. – LSX:A2P1AF
This article focuses on the "Enterprise value to EBIT forward" metric for Pulmonx Corp. (LSX:A2P1AF). It appears to be a financial data snippet from TradingView, providing an overview of a specific valuation ratio for the company's stock. The content points to financial data available on the platform, indicating market and company-specific information.
